secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2021-09-15T23:59:59+00:00
Accession:  0001104659-21-115681
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance cuts 75% of staff; ampreloxetine Phase 3 misses primary endpoint
---------------------------------------------------------------------------

- Headcount reduction of ~75% (~270 positions); most complete Nov 2021, remainder Feb 2022.
- Estimated $165M annualized operating expense savings in 2022; expects cash flow positive from 2H 2022.
- Ampreloxetine Phase 3 study (0169) failed to meet primary endpoint; no safety concerns.
- EVP & General Counsel Shafer resigns; SVP Sabesan leaves Nov 30; two directors (Whitesides, Gunderson) resign.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/tm2127424d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-115681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer